May 2012

May 23, 2012

Use of bioimpedance spectroscopy to aid in post“breast cancer assessments for lymphedema can be cost saving for healthcare organizations in the United States.

May 21, 2012

This study examines staff perceptions of patient care quality and the processes before and after implementation of a comprehensive clinical information system in 7 critical access hospitals.

May 18, 2012

A statewide collaboration between payers and providers to create a cancer clinical care pathways program is successful.

May 09, 2012

Active expert peer-to-peer consultation with prescribing oncologists can promote adherence to guidelines and lead to cost reductions without risk of neutropenic fever, with or without hospitalization, for patients with cancer.

May 09, 2012

As calls for improving the quality and cost efficiency of oncology increase, future empirical work is needed to examine the responsiveness of oncologists' treatment decision making to incentives among patients of all ages and insurance types.

May 09, 2012

Stereotactic body radiation therapy for low- to intermediate-risk prostate cancer has potential cost savings and may improve access to radiation, increase convenience, and boost quality of life.

May 09, 2012

This cost-utility analysis reports on the effect of quality of life on the value of screening all new patients with colorectal cancer for Lynch Syndrome.

May 09, 2012

Payment reform may be used to better align appropriate financial incentives with better quality of care.

May 08, 2012

Use of administrative claims data is an innovative way of measuring the effect of continuing medical education on physician practice behavior and patient outcomes.

May 08, 2012

Value-based insurance design copayment reductions sustained medication adherence 2 years into policy implementation and were most effective in patients with poor adherence before policy implementation.

May 08, 2012

The development of subspecialty tumor groups for uncommon malignancies represents an effective approach to building experience, increasing patient volumes and referrals, and fostering development of increased therapeutic options and clinical trials for patients afflicted with otherwise historically neglected cancers.